2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesDosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases
Laird J, Mokhtech M, Johung K, Park H, Jethwa K. Dosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e431-e432. DOI: 10.1016/j.ijrobp.2022.07.1640.Peer-Reviewed Original ResearchCRC lung metastasesInternal target volumeLung metastasesLocal controlPrescription dosesUnivariate analysisPrescription doseCox proportional hazards regression modelColorectal cancer lung metastasesProportional hazards regression modelsDosimetric parametersRetrospective cohort studyFavorable local controlImproved local controlLocal treatment optionsSingle cancer centerKaplan-Meier methodHazards regression modelsTarget volume dosesMATERIAL/METHODSMetastasis sizePTV D90Dosimetric predictorsMedian doseCohort studyImpact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer
Oh P, Laird J, Johung K. Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e197. DOI: 10.1016/j.ijrobp.2022.07.1113.Peer-Reviewed Original ResearchStereotactic body radiotherapyInternal target volumeUnivariate regression analysisGross tumor volumeOverall survivalLocal controlPancreatic cancerPerformance statusSBRT plansTarget volumeCox proportional hazards modelDosimetric parametersAdvanced unresectable diseaseImproved local controlRetrospective cohort studyUse of chemotherapyGood local controlKaplan-Meier methodPancreatic cancer patientsTarget volume sizeProportional hazards modelHigher gross tumor volumeMATERIAL/METHODSComprehensive dosimetric analysisUnresectable disease
2020
Radiation Therapy for Patients with Advanced Renal Cell Carcinoma
Miccio JA, Oladeru OT, Jun S, Johung KL. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics Of North America 2020, 47: 399-411. PMID: 32600541, DOI: 10.1016/j.ucl.2020.04.011.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaRadiation therapyMetastatic renal cell carcinomaExcellent local controlUse of radiotherapyBody radiation therapySelect patientsSurgical candidatesMetastatic sitesSurvival outcomesPrimary tumorImmune responseStereotactic radiosurgeryLocal controlPatientsMinimal toxicityCarcinomaTherapyFuture studiesPalliationRadiotherapyRadiosurgery
2019
When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
Miccio J, Johung K. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy. Oncology 2019, 33: 167-73, 177. PMID: 31095714.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyExcellent local control ratesMulti-fraction regimensExcellent local controlLocal control rateTreatment-related toxicityManagement of patientsSmall cohort sizeAdjuvant settingOligometastatic sitesNonsurgical patientsFraction radiationMetastatic sitesOnly palliationControl ratePrimary tumorTreatment approachesLocal controlCarcinomaTherapyPatients
2018
Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal Of Gastrointestinal Oncology 2018, 9: 982-988. PMID: 30603116, PMCID: PMC6286925, DOI: 10.21037/jgo.2018.04.03.Peer-Reviewed Original ResearchDistant metastasis-free survivalAdvanced pancreatic cancerConsolidative chemoradiationOverall survivalLocal controlPancreatic cancerMedian distant metastasis-free survivalCox proportional hazards modelCommon Terminology CriteriaEfficacy of FOLFIRINOXMedian overall survivalMore T4 tumorsMulti-agent chemotherapyR0 surgical resectionUse of FOLFIRINOXMonths of chemotherapyResponse Evaluation CriteriaKaplan-Meier analysisMetastasis-free survivalProportional hazards modelTerminology CriteriaProspective trialRadiographic responseSurgical resectionT3 tumors
2013
A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer
Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, Decker RH, Hess JA, Chiang VL, Contessa JN. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer. Clinical Cancer Research 2013, 19: 5523-5532. PMID: 23897899, DOI: 10.1158/1078-0432.ccr-13-0836.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGenotypeHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsRadiation ToleranceReceptor Protein-Tyrosine KinasesRecurrenceTranslocation, GeneticTumor BurdenConceptsNon-small cell lung cancerCell lung cancerEML4-ALK translocationGamma knife treatmentLocal controlTumor genotypeLung cancerEGFR mutationsCox proportional hazards modelDistant brain controlDistant brain recurrenceGamma knife radiotherapyEGFR kinase domain mutationsSuperior local controlField local controlKRAS mutation statusProportional hazards modelKinase domain mutationsEGF receptorMetastasis sizeBrain recurrenceBrain metastasesField recurrenceClinical outcomesIndependent predictors